The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation

Cell identity relies on the cross-talk between genetics and epigenetics and their impact on gene expression. Oxidation of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) is the first step of an active DNA demethylation process occurring mainly at enhancers and gene bodies and, as such, participates in processes governing cell identity in normal and pathological conditions. Although genetic alterations are well documented in multiple myeloma (MM), epigenetic alterations associated with this disease have not yet been thoroughly analyzed. To gain insight into the biology of MM, genome-wide 5hmC profiles were obtained and showed that regions enriched in this modified base overlap with MM enhancers and super enhancers and are close to highly expressed genes. Through the definition of a MM-specific 5hmC signature, we identified FAM72D as a poor prognostic gene located on 1q21, a region amplified in high risk myeloma. We further uncovered that FAM72D functions as part of the FOXM1 transcription factor network controlling cell proliferation and survival and we evidenced an increased sensitivity of cells expressing high levels of FOXM1 and FAM72 to epigenetic drugs targeting histone deacetylases and DNA methyltransferases.

[1]  D. Schatz,et al.  TET enzymes augment activation-induced deaminase (AID) expression via 5-hydroxymethylcytosine modifications at the Aicda superenhancer , 2019, Science Immunology.

[2]  G. Requirand,et al.  BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma , 2018, Cytometry. Part B, Clinical cytometry.

[3]  G. Requirand,et al.  PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs , 2018, Clinical Epigenetics.

[4]  R. Månsson,et al.  Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma. , 2018, Blood.

[5]  Stefan Wiemann,et al.  Assembly of a parts list of the human mitotic cell cycle machinery , 2018, bioRxiv.

[6]  A. Sérandour,et al.  Coupling Exonuclease Digestion with Selective Chemical Labeling forBase-resolution Mapping of 5-Hydroxymethylcytosine in Genomic DNA. , 2018, Bio-protocol.

[7]  G. Requirand,et al.  DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells , 2018, British Journal of Cancer.

[8]  G. Morgan,et al.  Evolutionary biology of high-risk multiple myeloma , 2017, Nature Reviews Cancer.

[9]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[10]  Nipun A. Mistry,et al.  ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. , 2017, Cancer cell.

[11]  Yi Zhang,et al.  TET-mediated active DNA demethylation: mechanism, function and beyond , 2017, Nature Reviews Genetics.

[12]  B. Klein,et al.  RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma , 2017, Leukemia.

[13]  B. Barlogie,et al.  Differentiation stage of myeloma plasma cells: biological and clinical significance , 2017, Leukemia.

[14]  Xiaosheng Wang,et al.  TP53 mutations, expression and interaction networks in human cancers , 2016, Oncotarget.

[15]  D. Hose,et al.  FOXM1 is a therapeutic target for high-risk multiple myeloma , 2016, Leukemia.

[16]  Michael Weber,et al.  Single-CpG resolution mapping of 5-hydroxymethylcytosine by chemical labeling and exonuclease digestion identifies evolutionarily unconserved CpGs as TET targets , 2016, Genome Biology.

[17]  Kathryn A. O’Donnell,et al.  Comprehensive Ex Vivo Transposon Mutagenesis Identifies Genes That Promote Growth Factor Independence and Leukemogenesis. , 2016, Cancer research.

[18]  K. Tarte,et al.  Cell-Cycle-Dependent Reconfiguration of the DNA Methylome during Terminal Differentiation of Human B Cells into Plasma Cells. , 2015, Cell reports.

[19]  S. Pramanik,et al.  All-or-(N)One - an epistemological characterization of the human tumorigenic neuronal paralogous FAM72 gene loci. , 2015, Genomics.

[20]  A. Rust,et al.  A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression , 2015, The Journal of experimental medicine.

[21]  Paul Flicek,et al.  Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers , 2015, Genome research.

[22]  S. Balasubramanian,et al.  oxBS-450K: A method for analysing hydroxymethylation using 450K BeadChips , 2015, Methods.

[23]  B. Barlogie,et al.  Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. , 2014, Blood.

[24]  Michael V. Gormally,et al.  Suppression of the FOXM1 transcriptional program via novel small molecule inhibition , 2014, Nature Communications.

[25]  P. Lin,et al.  A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. , 2014, Blood.

[26]  Yi Zhang,et al.  Regulation of TET protein stability by calpains. , 2014, Cell reports.

[27]  C. Eaves,et al.  Growth Arrest Specific 2 Is Up-Regulated in Chronic Myeloid Leukemia Cells and Required for Their Growth , 2014, PloS one.

[28]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[29]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[30]  G. Requirand,et al.  Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors , 2013, British Journal of Cancer.

[31]  T. Rème,et al.  Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells , 2013, PloS one.

[32]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[33]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[34]  Ansuman T. Satpathy,et al.  Dual actions of Meis1 inhibit erythroid progenitor development and sustain general hematopoietic cell proliferation. , 2012, Blood.

[35]  J. Eeckhoute,et al.  Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers , 2012, Nucleic acids research.

[36]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[37]  Clifford A. Meyer,et al.  Cistrome: an integrative platform for transcriptional regulation studies , 2011, Genome Biology.

[38]  C. Chai,et al.  Functional interaction of Ugene and EBV infection mediates tumorigenic effects , 2011, Oncogene.

[39]  Wing-Kin Sung,et al.  CENTDIST: discovery of co-associated factors by motif distribution , 2011, Nucleic Acids Res..

[40]  T. Rème,et al.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines , 2011, Haematologica.

[41]  P. Jin,et al.  Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine , 2011, Nature Biotechnology.

[42]  G. Morgan,et al.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.

[43]  M. Jourdan,et al.  Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation , 2010, Leukemia.

[44]  Cory Y. McLean,et al.  GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.

[45]  Bart Barlogie,et al.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. , 2009, Blood.

[46]  D. Sabatini,et al.  DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.

[47]  J. Willson,et al.  Ugene, a newly identified protein that is commonly overexpressed in cancer and binds uracil DNA glycosylase. , 2008, Cancer research.

[48]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[49]  B. Barlogie,et al.  Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2 , 2008, British journal of haematology.

[50]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[51]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[52]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[53]  John Crowley,et al.  Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. , 2006, Blood.

[54]  H. Stein,et al.  Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. , 2004, Blood.

[55]  B. Barlogie,et al.  Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. , 1998, Blood.